Cargando…

Beneficial effect of low-dose radioiodine ablation for Graves’ orbitopathy: results of a retrospective study

OBJECTIVE: Graves’ orbitopathy (GO) reflects an autoimmune response against antigens expressed by the thyroid and orbital tissues. Elimination of thyroid antigens may be beneficial for GO. Total thyroid ablation (TTA) [thyroidectomy (Tx), followed by 30 mCi of radioiodine] was shown to exert a benef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lanzolla, Giulia, Menconi, Francesca, Nicolì, Francesca, Posarelli, Chiara, Maglionico, Maria Novella, Figus, Michele, Nardi, Marco, Marcocci, Claudio, Marinò, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572201/ https://www.ncbi.nlm.nih.gov/pubmed/33844165 http://dx.doi.org/10.1007/s40618-021-01544-1

Ejemplares similares

Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

Sirolimus as a second-line treatment for Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

Antioxidant Therapy in Graves’ Orbitopathy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Graves’ disease and Graves’ orbitopathy following COVID-19
por: Lanzolla, G., et al.
Publicado: (2021)

Selenium in the Treatment of Graves’ Hyperthyroidism and Eye Disease
por: Lanzolla, Giulia, et al.
Publicado: (2021)

Combined Phacoemulsification and Ex-PRESS Implant with Everting Suture in Primary Angle-Closure Glaucoma: Survival Analysis and Predictive Factors
por: Covello, Giuseppe, et al.
Publicado: (2021)

Editorial: News in Graves’ orbitopathy: patients management and treatments
por: Lanzolla, Giulia, et al.
Publicado: (2023)

Thyroid Receptor Antibody and the Development of Graves’ Orbitopathy: Clinical Experience of using Radioiodine Ablation in the Management of Graves’ Orbitopathy in post-iodine ablation hypothyroid patient
por: Christina, Edelyn, et al.
Publicado: (2023)

Surgical complications in orbital decompression for Graves' orbitopathy
por: Sellari-Franceschini, S., et al.
Publicado: (2016)

Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Ophthalmological emergencies and the SARS-CoV-2 outbreak
por: Posarelli, Chiara, et al.
Publicado: (2020)

Reasons for revision surgery after orbital decompression for Graves’ orbitopathy
por: Sellari-Franceschini, Stefano, et al.
Publicado: (2008)

Time course of Graves’ orbitopathy after total thyroidectomy and radioiodine therapy for thyroid cancer
por: Louvet, Camille, et al.
Publicado: (2016)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
por: Perros, P., et al.
Publicado: (2017)

Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015)

Management of Graves’ hyperthyroidism and orbitopathy in time of COVID-19 pandemic
por: Bartalena, L., et al.
Publicado: (2020)

Asymmetric Graves’ Orbitopathy
por: Panagiotou, Grigorios, et al.
Publicado: (2020)

Effects of treatment modalities for Graves’ hyperthyroidism on Graves’ orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement
por: Bartalena, L., et al.
Publicado: (2015)

Radioiodine Thyroid Ablation in Graves’ Hyperthyroidism: Merits and Pitfalls
por: Nwatsock, J. F., et al.
Publicado: (2012)

Aqueous humour concentrations after topical apPlication of combinEd levofloxacin-dexamethasone eye dRops and of its single components: a randoMised, assEssor-blinded, parallel-group study in patients undergoing cataract surgery: the iPERME study
por: Figus, Michele, et al.
Publicado: (2020)

The Role of the Microbiota in Graves’ Disease and Graves’ Orbitopathy
por: Hou, Jueyu, et al.
Publicado: (2021)

Current Knowledge on Graves’ Orbitopathy
por: Gontarz-Nowak, Katarzyna, et al.
Publicado: (2020)

Orbital Signaling in Graves’ Orbitopathy
por: Draman, Mohd Shazli, et al.
Publicado: (2021)

A Clinical Picture of the Visual Outcome in Adamantiades-Behçet's Disease
por: Figus, Michele, et al.
Publicado: (2015)

Secondary epiretinal membrane after Ex-Press glaucoma filtration device implant
por: Loiudice, Pasquale, et al.
Publicado: (2020)

Graves′ orbitopathy: Management of difficult cases
por: Wiersinga, Wilmar M.
Publicado: (2012)

Endoscopic orbital decompression for Graves’ orbitopathy
por: Lal, Priti, et al.
Publicado: (2013)

Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2020)

Current concepts regarding Graves’ orbitopathy
por: Bartalena, Luigi, et al.
Publicado: (2022)

Update on the surgical management of Graves’ orbitopathy
por: Baeg, Joonyoung, et al.
Publicado: (2023)

Significance of HLA in the development of Graves’ orbitopathy
por: Stasiak, Magdalena, et al.
Publicado: (2023)

Long‐term outcome of supraciliary gold micro shunt in refractory glaucoma
por: Figus, Michele, et al.
Publicado: (2021)

Planning health care for patients with Graves’ orbitopathy
por: Sasim, Inna V., et al.
Publicado: (2008)

Mechanisms That Underly T Cell Immunity in Graves’ Orbitopathy
por: Fang, Sijie, et al.
Publicado: (2021)

Serum thyroglobulin is associated with orbitopathy in Graves’ disease
por: Khamisi, S., et al.
Publicado: (2021)

Correction to: Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2021)

Roles of four targets in the pathogenesis of graves' orbitopathy
por: Ren, Ziqiang, et al.
Publicado: (2023)

Atypical Asymmetric Presentation of Severe Graves’ Orbitopathy
por: Gupta, Priyanka, et al.
Publicado: (2023)

Asymmetry indicates more severe and active disease in Graves’ orbitopathy: results from a prospective cross-sectional multicentre study
por: Perros, P., et al.
Publicado: (2020)

Biologic Agents in Inflammatory Eye Disease
por: Posarelli, Chiara, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_b55qaf8l1g8b7tgs9a7pl2q555